Nonsteroidal therapy for idiopathic pulmonary fibrosis

Current Opinion in Pulmonary Medicine

Volumn 7, Issue 5, 2001, Pages 309-313

  Baughman, Robert P ^a   Alabi, Fortune O ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC AGENT; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; OXYGEN RADICAL; PIRFENIDONE; PREDNISONE; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; COLLAGEN DISEASE; INFLAMMATION; LUNG FIBROSIS; LUNG LAVAGE; LUNG TRANSPLANTATION; REVIEW; TH2 CELL;

EID: 0034805926     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200109000-00010     Document Type: Review

References (49)

1. Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification
2. Nonspecific interstitial pneumonia/fibrosis: Histologic features and clinical significance
3. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement
4. Management of interstitial lung disease: State of the art
5. Determinants of survival in idiopathic pulmonary fibrosis
6. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: A prospective double-blind randomized, placebo controlled clinical trial
7. Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisone in combination in cryptogenic fibrosing alveolitis
8. Local production of intedeukin-4 during radiation-induced pneumonitis and pulmonary fibrosis in rats: Macrophages as a prominent source of inteleukin-4
9. Altered accessory cell function of alveolar macrophages: A possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis
10. Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis
11. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease
12. Therapy for severe interstitial lung disease in systemic sclerosis: A retrospective study
13. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis
14. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma
15. Outcome cf subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: Implications for further studies
16. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: A prospective study in patients who failed to respond to corticosteroids
17. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis
18. Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis
19. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis
20. Cryptogenic fibrosing alveolitis: Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis
21. Efficacy of cyclosporine to reduce steroids in patients with idiopathic pulmonary fibrosis before lung transplantation
22. Idiopathic pulmonary fibrosis and cyclosporine: A lesson from single-lung transplantation
23. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: Downregulation of TGF-beta and procollagen I and III gene expression
24. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis
25. Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis
26. Mechanisms of antifibrotic action of interferon gamma-1b in pulmonary fibrosis
27. Interferon-alpha therapy associated with the development of sarcoidosis
28. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C
29. Antiinflammatory and antifibrotic properties of colchicine: Implications for idiopathic pulmonary fibrosis
30. Colchicine in the treatment of pulmonary fibrosis
31. Colchicine versus prednisone as treatment of usual interstitial pneumonia
32. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival
33. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model
34. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label Phase II study
35. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters
36. Respiratory epithelial cell expression of human transforming growth factor-alpha induces lung fibrosis in transgenic mice
37. Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis
38. Transforming growth factor-alpha deficiency reduces pulmonary fibrosis in transgenic mice
39. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice
40. Etanercept and methotrexate combination therapy
41. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
42. Infliximab for refractory sarcoidosis
43. Oral N-acetyfcysteine reduces bleomycin-induced collagen deposition in the lungs of mice
44. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis: Adjunctive therapy to maintenance immunosuppression
45. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis
46. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue
47. Lack of effect of N-acetylcysteine on the release of oxygen radicals from neutrophils and alveolar macrophages
48. Therapy for interstitial lung disease
49. Idiopathic pulmonary fibrosis: Predicting response to therapy and survival